News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Treatment-experienced people
Once-daily elvitegravir works as well as raltegravir at 96 weeks

The investigational HIV integrase inhibitor elvitegravir taken once daily continued to perform as well as twice-daily raltegravir (Isentress) at 96 weeks for treatment-experienced people with extensive drug resistance,

Published
31 July 2012
By
Liz Highleyman
New and experimental HIV treatments
ViiV Announces Expanded Access to Once-a-Day Integrase Inhibitor ... But Activists Are Concerned About Its Potential Misuse

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare's investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy.

Published
09 March 2012
From
The Body
New and experimental HIV treatments
EACS: Does Maraviroc Intensification Promote Better CD4 Cell Recovery?

Adding maraviroc (Selzentry or Celsentri) to a suppressive antiretroviral regimen may help promote CD4 T-cell recovery in a subset of patients who experience poor immunological response to treatment, according to 2 studies presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.

Published
27 October 2011
From
HIVandhepatitis.com
Treatment-experienced people
HIV Drug Resistance Effect Damped Down over Time

The proportion of HIV patients who are able to suppress the virus despite extensive drug resistance nearly tripled over a 10-year period, researchers reported.

Published
10 October 2011
From
MedPage Today
Treatment-experienced people
Low stock: HIV patients denied second-line drugs

About 750 HIV patients requiring advanced treatment in the state are forced to go without life-saving second-line anti-retroviral therapy (ART) drugs which are in short supply.

Published
07 August 2011
From
Times of India
New and experimental HIV treatments
Once-daily elvitegravir matches raltegravir

The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well tolerated overall, according to data presented at

Published
21 July 2011
By
Liz Highleyman
Treatment-experienced people
Is there a future for HIV-infected patients in deep salvage?

Most of us built resistance as we joined study after study that exposed us to functional monotherapy. In fact, I consider many of us who have been struggling with multiple drug resistance to be wounded soldiers from a time when we were recruited into studies we joined out of desperation to access a new drug.

Published
04 May 2011
From
The Body
Treatment-experienced people
Cipla seeks voluntary license for anti-HIV Isentress

Isentress in India has been launched by Merck at a fourth of its US prices — that’s USD 7 for a day’s treatment as against USD 28 in the US. Cipla says it is not reaching needy patients in India and is priced exorbitantly>

Published
04 April 2011
From
Moneycontrol.com
New and experimental HIV treatments
What Lies Ahead: An Activist's View of Promising HIV Treatment Research

After attending the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Mass., and following different areas of research, I decided to write down a list of advancements that really thrill and energize me as an educator and research advocate.

Published
31 March 2011
From
The Body
Treatment-experienced people
Zambia: 'Only Four Percent Need Third Line ARV Treatment'

Only four per cent of patients on ARVs need second or third line treatment, the Ministry of Health has said.

Published
15 March 2011
From
AllAfrica
← Prev1...34567...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.